Barclays Reiterates Buy Rating on SHC with $19 Price Target
Barclays' analyst Luke Sergott maintains a buy rating on SHC, setting a price target of $19, a 10.82% upside from the current price.
Key Points
- Barclays' analyst Luke Sergott reiterated a buy rating on SHC with a price target of $19 as of June 24, 2026.
- Barclays's $19 price target implies 10.82% upside from Sotera Health Company's ($SHC) current $17.14 share price.
- Shares of SHC traded near $16.30 on Wednesday, June 24, 2026.
- Darsana Capital Partners holds 26 million shares of SHC, while BlackRock increased its stake by 2,770,086 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Barclays' analyst Luke Sergott reiterated a buy rating on SHC, setting a price target of $19. This announcement comes as part of Barclays' ongoing coverage of the company.
Barclays vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in SHC
Darsana Capital Partners maintained its stake in SHC with 26 million shares valued at approximately $372.84 million. Sessa Capital IM, L.P. increased its holdings by 2.5 million shares, bringing its total to 23.05 million shares worth about $330.54 million, marking a 12.2% increase. Sculptor Capital LP also added 717,728 shares, ending with 21.72 million shares valued at $311.43 million, a 3.4% boost. BlackRock, Inc. increased its investment by 2,770,086 shares, now holding 20.85 million shares worth roughly $298.98 million, a 15.3% increase. Meanwhile, Warburg Pincus LLC reduced its stake by 15 million shares, closing with 19.1 million shares, a 44% decrease.
Sotera Health Company Stock Down 11.0%
Shares of SHC traded near $16.30 on Wednesday, June 24, 2026. While specific financial metrics such as market cap, P/E ratio, and beta were not disclosed, the stock's recent activity reflects ongoing interest and adjustments by institutional investors.
$SHC price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Sotera Health Company
On May 26, 2026, Alton Shader, SHC's Chief Executive Officer, made multiple purchases totaling 681,390 shares. Additionally, on May 22, 2026, insiders James Neary, Vincent Petrella, and David Wheadon each bought 14,970 shares. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On June 24, 2026, Barclays maintained its buy rating on SHC with a $19 price target. Earlier, on June 5, 2026, Goldman Sachs initiated coverage with a buy rating and a $20 target. Piper Sandler reiterated a buy rating with a $22 target on May 6, 2026. The analyst consensus remains positive, with several firms maintaining buy ratings and targets ranging from $19 to $24.
Bottom Line
Barclays' reaffirmation of a buy rating on SHC with a $19 target highlights continued confidence in the company's prospects. Institutional activity shows mixed adjustments, with some funds increasing their stakes while others reduce theirs. Insider buying suggests optimism among SHC's leadership. Investors should note that these ratings and transactions reflect past decisions and may not indicate current positions.
Get Sotera Health Company alerts
New 13F filings, insider trades, and analyst moves on $SHC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.